SlideShare ist ein Scribd-Unternehmen logo
1 von 16
Comers To the Market
                                                            (CTM)
                                                          Walid Saafan
                                                    Marketing Information Manager
                                                            Novartis Egypt




1 Comers To the Market (CTM)-Presentation / Egypt
Topics


 Objectives
 CTM Inputs
 CTM concept
 CTM Deliverables
 CTM analysis
 Key success factors
 Conclusion
Objectives


 Monthly follow-up to New Introductions (NIs) and
 Life Cycle Management (LCM) introduced in the
 market.
 Full information about NIs/ LCM brands/ packs.
 Calculate the YTD sales impact on NIs/ LCMs on
 market(s) and corporate.
CTM update cycle
 taview report        2. Paste data into Excel tool




CTM report is ready
CTM concept


 Extract IMS Dataview report data into an Excel
 tool that re-format the data for CTM report.
 Differentiate between NI/ LCM by units sold LY. If
 Brand previous years units sold=0  NI otherwise
 LCM
 Provide all information about NIs/ LCMs brands:
 ATC3, CRP, Brand, Pack, MOL, NI/ LCM YTD
 sales, launch Month, Launch year, PSP.
 Ability to filter the report by ATC3 or CRP.
CTM deliverables – Total market
  ATC3        CRP         Brand      Pack            Mol(s)         NIs count

                                                                                LCMs count




                                            NIs YTD sales

                                                   LCMs YTD sales




                                             NI YTD sales


                                            LCM YTD sales




   Source:   CTM / IMS data Dec.06
CTM deliverables – specific ATC3
Select Class




   All results filtered on the selected class.
   New competitors information available.
   PM can follow up brands/ generics introductions
   in his market(s).
         Source:   CTM / IMS data Dec.06
CTM deliverables – specific CRP
      Select CRP




 All results filtered on the selected CRP.
 Analysis of CRPs YTD growth derived from NIs/LCM.
 Identify introduced brands by the selected CRP.

   Source:   CTM / IMS data Dec.06
CTM analysis – Leading CRPs in LCM




 Arrange CRPs in terms of YTD LCM value sales.
 Assess YTD impact of CRP new packs introduced.


   Source:   CTM / IMS data Dec.06
CTM analysis – Leading CRPs in NIs




 Arrange CRPs in terms of YTD Nis value sales.
 Assess YTD impact of CRP new brands introduced.


   Source:   CTM / IMS data Dec.06
CTM analysis – Leading ATC3 in NIs




 Arranged classes in terms of NIs to identify the attractive
 markets.
 Assess current classes that our brands compete in.

   Source:   CTM / IMS data Dec.06
CTM analysis – Leading ATC3 in LCMs




 Arranged classes in terms of LCMs to identify the
 attractive markets.
 Assess current classes that our brands compete in.

   Source:   CTM / IMS data Dec.06
Sample outputs
ading CRPs - LCM
                  Others (180),
                23,799,000 , 22%


                                                              NOVARTIS, 39,246,800
   SANOFI AVENTIS,                                                  , 35%
    2,127,700 , 2%


MERCK AG*, 3,043,000
       , 3%
  GLAXOSMITHKLINE*,
    3,471,600 , 3%
    AMOUN PHARM.CO.,
      3,896,400 , 4%
        EVA, 4,979,400 , 5%
            ABBOTT*, 5,117,000 ,
                                                           LCM breakdown per CRP
                                                       PFIZER*, 8,972,900 ,
                                                               8%    45,000,000
                   5%
                                             ALTANA*, 7,037,600 ,                                                                              MIACALCIC PLUS
                  LUNDBEC., 6,423,900 ,                                                                                  SIRDALUD 2mg 20
                                                     7%                                                                                       (08.2006), 615,300
                         6%                                          40,000,000                                          (07.2006), 542,500


                                                                                                                                  VOLTAREN AMP 75mg 6
                                                                     35,000,000
                                                                                                                                   (04.2006), 6,362,100

                                                                                                                       CATAFLAM AMP 75mg 6
                                                                     30,000,000
                                                                                                                        (04.2006) , 4,156,400
                                                                                                           ANAFRONIL 75mg 20
                                                                     25,000,000                            (02.2006), 4,306,600


                                                                     20,000,000                                                                           38.6 Mio
                                                                                                CATAFLAM 50mg 20
                                                                     15,000,000                (02.2006), 13,232,700



                                                                     10,000,000

                                                                                     FLOTAC (01.2006),
                                                                      5,000,000
                                                                                        10,031,300
                       Source:       CTM / IMS data Dec.06
                                                                            -
                                                                                                         Novartis PH
Key success factors


 Tool update can be done easily without too much
 technical knowledge (preliminary Dataview and Excel
 experience).
 Tool is applied in Novartis Egypt for almost a year and
 introduced to Novartis KSA from Oct.06.
 PMs follow up introductions in their markets on monthly
 basis or during MPH planning.
 CPO management assess their position in the market and
 follow up competitor launches on monthly basis or during
 planning or StratPlan preperation.
 BD&L can analyze the market and identify attractive
 markets in terms of number/ value of NIs & LCMs.
Conclusion


 CTM is an easy tool that give more insight about
 market dynamics.
 The tool can be adapted easily in different
 markets from small CPOs to regional level.
 Many new untapped information can be explored
 that will support marketing and senior
 management to analyze market dynamics.
 Consolidated reports can easily extracted with
 pivot reports.
Thanks


16 Comers To the Market (CTM)-Presentation / Egypt

Weitere Àhnliche Inhalte

Was ist angesagt?

Pharma marketing
Pharma marketingPharma marketing
Pharma marketingUzair Ahmed
 
African Medicines Regulatory Harmonisation
African Medicines Regulatory Harmonisation African Medicines Regulatory Harmonisation
African Medicines Regulatory Harmonisation PharmaAfrica
 
Medical affairs department for small organization
Medical affairs department for small organizationMedical affairs department for small organization
Medical affairs department for small organizationDr. Zubair Ali
 
The future of pharma marketing
The future of pharma marketingThe future of pharma marketing
The future of pharma marketingFarhad Zargari
 
Reporting of pharmacovigilance and role of pharmacist
Reporting of pharmacovigilance and role of pharmacistReporting of pharmacovigilance and role of pharmacist
Reporting of pharmacovigilance and role of pharmacistDr. Ramesh Bhandari
 
Clinical Trials Strategy: The Clinical Development Plan
Clinical Trials Strategy: The Clinical Development PlanClinical Trials Strategy: The Clinical Development Plan
Clinical Trials Strategy: The Clinical Development PlanMaRS Discovery District
 
Me rck’s new product development & launch strategy for
Me rck’s new product development & launch strategy for Me rck’s new product development & launch strategy for
Me rck’s new product development & launch strategy for First Economy
 
Benchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs FunctionsBenchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs FunctionsIndustry Standard Research
 
New drug and ct rules 2019
New drug and ct rules 2019New drug and ct rules 2019
New drug and ct rules 2019Prasad Bhat
 
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...IHS
 
Drugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDrugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDr. Vishal Pawar
 
Pharmaceutical Business Development Process Flow
Pharmaceutical Business Development Process FlowPharmaceutical Business Development Process Flow
Pharmaceutical Business Development Process FlowMuhammad Ali Jehangir
 
Medical Affairs
Medical AffairsMedical Affairs
Medical Affairsmbielick
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceMd. Zakaria Faruki
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)Saiyad Arsh zia
 
Pharmaceutical competitive intelligence
Pharmaceutical competitive intelligencePharmaceutical competitive intelligence
Pharmaceutical competitive intelligenceferiel abidi
 
Anvisa gudelines
Anvisa gudelinesAnvisa gudelines
Anvisa gudelinesAnkit Gotecha
 

Was ist angesagt? (20)

Pharma marketing
Pharma marketingPharma marketing
Pharma marketing
 
African Medicines Regulatory Harmonisation
African Medicines Regulatory Harmonisation African Medicines Regulatory Harmonisation
African Medicines Regulatory Harmonisation
 
Medical affairs department for small organization
Medical affairs department for small organizationMedical affairs department for small organization
Medical affairs department for small organization
 
The future of pharma marketing
The future of pharma marketingThe future of pharma marketing
The future of pharma marketing
 
Reporting of pharmacovigilance and role of pharmacist
Reporting of pharmacovigilance and role of pharmacistReporting of pharmacovigilance and role of pharmacist
Reporting of pharmacovigilance and role of pharmacist
 
Clinical Trials Strategy: The Clinical Development Plan
Clinical Trials Strategy: The Clinical Development PlanClinical Trials Strategy: The Clinical Development Plan
Clinical Trials Strategy: The Clinical Development Plan
 
Me rck’s new product development & launch strategy for
Me rck’s new product development & launch strategy for Me rck’s new product development & launch strategy for
Me rck’s new product development & launch strategy for
 
Benchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs FunctionsBenchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs Functions
 
EU Clinical Trials Regulation.. Summarised
EU Clinical Trials Regulation.. SummarisedEU Clinical Trials Regulation.. Summarised
EU Clinical Trials Regulation.. Summarised
 
New drug and ct rules 2019
New drug and ct rules 2019New drug and ct rules 2019
New drug and ct rules 2019
 
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
 
Drugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDrugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan Drugs
 
Pharmaceutical Business Development Process Flow
Pharmaceutical Business Development Process FlowPharmaceutical Business Development Process Flow
Pharmaceutical Business Development Process Flow
 
BA and BE studies
BA and BE studiesBA and BE studies
BA and BE studies
 
Medical Affairs
Medical AffairsMedical Affairs
Medical Affairs
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and Pharmacovigilance
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
Pharmaceutical competitive intelligence
Pharmaceutical competitive intelligencePharmaceutical competitive intelligence
Pharmaceutical competitive intelligence
 
505 (b) (2)
505 (b) (2)505 (b) (2)
505 (b) (2)
 
Anvisa gudelines
Anvisa gudelinesAnvisa gudelines
Anvisa gudelines
 

Ähnlich wie PHARMA-How to Identify NI & LCM from IMS data

EGYPT Osteoporosis market analysis 2010
EGYPT Osteoporosis market analysis 2010EGYPT Osteoporosis market analysis 2010
EGYPT Osteoporosis market analysis 2010Walid Saafan
 
Walid saafan pharma_experience
Walid saafan pharma_experienceWalid saafan pharma_experience
Walid saafan pharma_experienceWalid Saafan
 
Btf exhibitors presentation, atlantis, 5 25-12
Btf exhibitors presentation, atlantis, 5 25-12Btf exhibitors presentation, atlantis, 5 25-12
Btf exhibitors presentation, atlantis, 5 25-12pmcurran1
 
Process flow of sales forecasting and supply chain
Process flow of  sales forecasting and supply chainProcess flow of  sales forecasting and supply chain
Process flow of sales forecasting and supply chainHpm India
 
merck 4Q06 Other Financial Disclosures
merck  	4Q06 Other Financial Disclosuresmerck  	4Q06 Other Financial Disclosures
merck 4Q06 Other Financial Disclosuresfinance11
 
Iochpe-Maxion - 1Q09 Results Presentation
Iochpe-Maxion - 1Q09 Results PresentationIochpe-Maxion - 1Q09 Results Presentation
Iochpe-Maxion - 1Q09 Results PresentationIochpe-Maxion
 
Team Professionals VMobile Presentation Updated
Team Professionals VMobile Presentation UpdatedTeam Professionals VMobile Presentation Updated
Team Professionals VMobile Presentation UpdatedDory Mendros
 
Iochpe-Maxion - 3Q09 Presentation
Iochpe-Maxion - 3Q09 PresentationIochpe-Maxion - 3Q09 Presentation
Iochpe-Maxion - 3Q09 PresentationIochpe-Maxion
 
2008 Mediakit Action
2008 Mediakit Action2008 Mediakit Action
2008 Mediakit Actionlainacasey
 
Presentacin indijun2009
Presentacin indijun2009Presentacin indijun2009
Presentacin indijun2009redasomi
 
Biopower in australia
Biopower in australiaBiopower in australia
Biopower in australiaNelson Permal
 
Q1 2009 Analyst Presentation Final
Q1 2009 Analyst Presentation FinalQ1 2009 Analyst Presentation Final
Q1 2009 Analyst Presentation FinalRodrigo Aguilera
 
Asml 20070914 2007 09 14 Db London Sept 14
Asml 20070914 2007 09 14 Db London Sept 14Asml 20070914 2007 09 14 Db London Sept 14
Asml 20070914 2007 09 14 Db London Sept 14angsikod
 
Stock quotes 11112014
Stock quotes 11112014Stock quotes 11112014
Stock quotes 11112014srichardequip
 
Stock quotes 11122014
Stock quotes 11122014Stock quotes 11122014
Stock quotes 11122014srichardequip
 
European Markets for Cardiac Surgery Devices
European Markets for Cardiac Surgery DevicesEuropean Markets for Cardiac Surgery Devices
European Markets for Cardiac Surgery DevicesReportLinker.com
 
merck 3Q06 Other Financial
merck  	3Q06 Other Financialmerck  	3Q06 Other Financial
merck 3Q06 Other Financialfinance11
 
2008 Hwacheon Master Action Plan
2008 Hwacheon Master Action Plan2008 Hwacheon Master Action Plan
2008 Hwacheon Master Action PlanMarkALeeser
 

Ähnlich wie PHARMA-How to Identify NI & LCM from IMS data (20)

EGYPT Osteoporosis market analysis 2010
EGYPT Osteoporosis market analysis 2010EGYPT Osteoporosis market analysis 2010
EGYPT Osteoporosis market analysis 2010
 
Walid saafan pharma_experience
Walid saafan pharma_experienceWalid saafan pharma_experience
Walid saafan pharma_experience
 
Btf exhibitors presentation, atlantis, 5 25-12
Btf exhibitors presentation, atlantis, 5 25-12Btf exhibitors presentation, atlantis, 5 25-12
Btf exhibitors presentation, atlantis, 5 25-12
 
Process flow of sales forecasting and supply chain
Process flow of  sales forecasting and supply chainProcess flow of  sales forecasting and supply chain
Process flow of sales forecasting and supply chain
 
merck 4Q06 Other Financial Disclosures
merck  	4Q06 Other Financial Disclosuresmerck  	4Q06 Other Financial Disclosures
merck 4Q06 Other Financial Disclosures
 
Iochpe-Maxion - 1Q09 Results Presentation
Iochpe-Maxion - 1Q09 Results PresentationIochpe-Maxion - 1Q09 Results Presentation
Iochpe-Maxion - 1Q09 Results Presentation
 
Team Professionals VMobile Presentation Updated
Team Professionals VMobile Presentation UpdatedTeam Professionals VMobile Presentation Updated
Team Professionals VMobile Presentation Updated
 
Iochpe-Maxion - 3Q09 Presentation
Iochpe-Maxion - 3Q09 PresentationIochpe-Maxion - 3Q09 Presentation
Iochpe-Maxion - 3Q09 Presentation
 
2008 Mediakit Action
2008 Mediakit Action2008 Mediakit Action
2008 Mediakit Action
 
Presentacin indijun2009
Presentacin indijun2009Presentacin indijun2009
Presentacin indijun2009
 
Biopower in australia
Biopower in australiaBiopower in australia
Biopower in australia
 
Q1 2009 Analyst Presentation Final
Q1 2009 Analyst Presentation FinalQ1 2009 Analyst Presentation Final
Q1 2009 Analyst Presentation Final
 
Asml 20070914 2007 09 14 Db London Sept 14
Asml 20070914 2007 09 14 Db London Sept 14Asml 20070914 2007 09 14 Db London Sept 14
Asml 20070914 2007 09 14 Db London Sept 14
 
Stock quotes 11112014
Stock quotes 11112014Stock quotes 11112014
Stock quotes 11112014
 
Stock quotes 11122014
Stock quotes 11122014Stock quotes 11122014
Stock quotes 11122014
 
European Markets for Cardiac Surgery Devices
European Markets for Cardiac Surgery DevicesEuropean Markets for Cardiac Surgery Devices
European Markets for Cardiac Surgery Devices
 
Presentation2
Presentation2Presentation2
Presentation2
 
Presentation2
Presentation2Presentation2
Presentation2
 
merck 3Q06 Other Financial
merck  	3Q06 Other Financialmerck  	3Q06 Other Financial
merck 3Q06 Other Financial
 
2008 Hwacheon Master Action Plan
2008 Hwacheon Master Action Plan2008 Hwacheon Master Action Plan
2008 Hwacheon Master Action Plan
 

Mehr von Walid Saafan

Mclaren the banking sector v2
Mclaren the banking sector v2Mclaren the banking sector v2
Mclaren the banking sector v2Walid Saafan
 
EGP flotation impact on some banks
EGP flotation impact on some banksEGP flotation impact on some banks
EGP flotation impact on some banksWalid Saafan
 
ABK Egypt financial statements H1 18
ABK Egypt financial statements H1 18ABK Egypt financial statements H1 18
ABK Egypt financial statements H1 18Walid Saafan
 
ABK Egypt financials' summary H1-18
ABK Egypt financials' summary H1-18ABK Egypt financials' summary H1-18
ABK Egypt financials' summary H1-18Walid Saafan
 
NBK Egypt financial statement H1-18
NBK Egypt financial statement H1-18NBK Egypt financial statement H1-18
NBK Egypt financial statement H1-18Walid Saafan
 
NBK-Egypt financials summary H1-18
NBK-Egypt financials summary H1-18NBK-Egypt financials summary H1-18
NBK-Egypt financials summary H1-18Walid Saafan
 
Facebook effect on SMEs in Egypt
Facebook effect on SMEs in EgyptFacebook effect on SMEs in Egypt
Facebook effect on SMEs in EgyptWalid Saafan
 
Infographic: Fastest growing Egyptian banks in t.assets 03.2016
Infographic: Fastest growing Egyptian banks in t.assets 03.2016Infographic: Fastest growing Egyptian banks in t.assets 03.2016
Infographic: Fastest growing Egyptian banks in t.assets 03.2016Walid Saafan
 
Branch location for selected banks
Branch location for selected banksBranch location for selected banks
Branch location for selected banksWalid Saafan
 
Entrepreneurship as disease
Entrepreneurship as diseaseEntrepreneurship as disease
Entrepreneurship as diseaseWalid Saafan
 
Corporate values' Evaluation
Corporate values' EvaluationCorporate values' Evaluation
Corporate values' EvaluationWalid Saafan
 
Strategic Alliance
Strategic AllianceStrategic Alliance
Strategic AllianceWalid Saafan
 
'Blue Ocean Strategy' book review
'Blue Ocean Strategy' book review'Blue Ocean Strategy' book review
'Blue Ocean Strategy' book reviewWalid Saafan
 
Egypt privatization program
Egypt privatization programEgypt privatization program
Egypt privatization programWalid Saafan
 
Strategic Alliance failure
Strategic Alliance failureStrategic Alliance failure
Strategic Alliance failureWalid Saafan
 
Basel II – Integrated Risk Capital
Basel II – Integrated Risk CapitalBasel II – Integrated Risk Capital
Basel II – Integrated Risk CapitalWalid Saafan
 
Options trading markets
Options trading marketsOptions trading markets
Options trading marketsWalid Saafan
 
How are banking ratios compiled
How are banking ratios compiledHow are banking ratios compiled
How are banking ratios compiledWalid Saafan
 
Corporate culture a source for competitive advantage
Corporate culture a source for competitive advantageCorporate culture a source for competitive advantage
Corporate culture a source for competitive advantageWalid Saafan
 
What is STRATEGY?
What is STRATEGY?What is STRATEGY?
What is STRATEGY?Walid Saafan
 

Mehr von Walid Saafan (20)

Mclaren the banking sector v2
Mclaren the banking sector v2Mclaren the banking sector v2
Mclaren the banking sector v2
 
EGP flotation impact on some banks
EGP flotation impact on some banksEGP flotation impact on some banks
EGP flotation impact on some banks
 
ABK Egypt financial statements H1 18
ABK Egypt financial statements H1 18ABK Egypt financial statements H1 18
ABK Egypt financial statements H1 18
 
ABK Egypt financials' summary H1-18
ABK Egypt financials' summary H1-18ABK Egypt financials' summary H1-18
ABK Egypt financials' summary H1-18
 
NBK Egypt financial statement H1-18
NBK Egypt financial statement H1-18NBK Egypt financial statement H1-18
NBK Egypt financial statement H1-18
 
NBK-Egypt financials summary H1-18
NBK-Egypt financials summary H1-18NBK-Egypt financials summary H1-18
NBK-Egypt financials summary H1-18
 
Facebook effect on SMEs in Egypt
Facebook effect on SMEs in EgyptFacebook effect on SMEs in Egypt
Facebook effect on SMEs in Egypt
 
Infographic: Fastest growing Egyptian banks in t.assets 03.2016
Infographic: Fastest growing Egyptian banks in t.assets 03.2016Infographic: Fastest growing Egyptian banks in t.assets 03.2016
Infographic: Fastest growing Egyptian banks in t.assets 03.2016
 
Branch location for selected banks
Branch location for selected banksBranch location for selected banks
Branch location for selected banks
 
Entrepreneurship as disease
Entrepreneurship as diseaseEntrepreneurship as disease
Entrepreneurship as disease
 
Corporate values' Evaluation
Corporate values' EvaluationCorporate values' Evaluation
Corporate values' Evaluation
 
Strategic Alliance
Strategic AllianceStrategic Alliance
Strategic Alliance
 
'Blue Ocean Strategy' book review
'Blue Ocean Strategy' book review'Blue Ocean Strategy' book review
'Blue Ocean Strategy' book review
 
Egypt privatization program
Egypt privatization programEgypt privatization program
Egypt privatization program
 
Strategic Alliance failure
Strategic Alliance failureStrategic Alliance failure
Strategic Alliance failure
 
Basel II – Integrated Risk Capital
Basel II – Integrated Risk CapitalBasel II – Integrated Risk Capital
Basel II – Integrated Risk Capital
 
Options trading markets
Options trading marketsOptions trading markets
Options trading markets
 
How are banking ratios compiled
How are banking ratios compiledHow are banking ratios compiled
How are banking ratios compiled
 
Corporate culture a source for competitive advantage
Corporate culture a source for competitive advantageCorporate culture a source for competitive advantage
Corporate culture a source for competitive advantage
 
What is STRATEGY?
What is STRATEGY?What is STRATEGY?
What is STRATEGY?
 

KĂŒrzlich hochgeladen

97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 
Book Call Girls in Yelahanka - For 7001305949 Cheap & Best with original Photos
Book Call Girls in Yelahanka - For 7001305949 Cheap & Best with original PhotosBook Call Girls in Yelahanka - For 7001305949 Cheap & Best with original Photos
Book Call Girls in Yelahanka - For 7001305949 Cheap & Best with original Photosnarwatsonia7
 
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...narwatsonia7
 
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...narwatsonia7
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking ModelsMumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Modelssonalikaur4
 
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...narwatsonia7
 
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service JaipurHigh Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipurparulsinha
 
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service LucknowCall Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknownarwatsonia7
 
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...narwatsonia7
 
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service LucknowVIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknownarwatsonia7
 
Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000
Ahmedabad Call Girls CG Road 🔝9907093804  Short 1500  💋 Night 6000Ahmedabad Call Girls CG Road 🔝9907093804  Short 1500  💋 Night 6000
Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000aliya bhat
 
VIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service Mumbai
VIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service MumbaiVIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service Mumbai
VIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service Mumbaisonalikaur4
 
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy GirlsCall Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girlsnehamumbai
 
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment BookingCall Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Bookingnarwatsonia7
 
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 

KĂŒrzlich hochgeladen (20)

97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
 
Book Call Girls in Yelahanka - For 7001305949 Cheap & Best with original Photos
Book Call Girls in Yelahanka - For 7001305949 Cheap & Best with original PhotosBook Call Girls in Yelahanka - For 7001305949 Cheap & Best with original Photos
Book Call Girls in Yelahanka - For 7001305949 Cheap & Best with original Photos
 
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
 
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
 
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking ModelsMumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
 
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
 
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service JaipurHigh Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
 
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service LucknowCall Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
 
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...
Call Girls Frazer Town Just Call 7001305949 Top Class Call Girl Service Avail...
 
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service LucknowVIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
 
Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000
Ahmedabad Call Girls CG Road 🔝9907093804  Short 1500  💋 Night 6000Ahmedabad Call Girls CG Road 🔝9907093804  Short 1500  💋 Night 6000
Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000
 
VIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service Mumbai
VIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service MumbaiVIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service Mumbai
VIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service Mumbai
 
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy GirlsCall Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
 
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment BookingCall Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
Call Girl Koramangala | 7001305949 At Low Cost Cash Payment Booking
 
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
 

PHARMA-How to Identify NI & LCM from IMS data

  • 1. Comers To the Market (CTM) Walid Saafan Marketing Information Manager Novartis Egypt 1 Comers To the Market (CTM)-Presentation / Egypt
  • 2. Topics Objectives CTM Inputs CTM concept CTM Deliverables CTM analysis Key success factors Conclusion
  • 3. Objectives Monthly follow-up to New Introductions (NIs) and Life Cycle Management (LCM) introduced in the market. Full information about NIs/ LCM brands/ packs. Calculate the YTD sales impact on NIs/ LCMs on market(s) and corporate.
  • 4. CTM update cycle taview report 2. Paste data into Excel tool CTM report is ready
  • 5. CTM concept Extract IMS Dataview report data into an Excel tool that re-format the data for CTM report. Differentiate between NI/ LCM by units sold LY. If Brand previous years units sold=0  NI otherwise LCM Provide all information about NIs/ LCMs brands: ATC3, CRP, Brand, Pack, MOL, NI/ LCM YTD sales, launch Month, Launch year, PSP. Ability to filter the report by ATC3 or CRP.
  • 6. CTM deliverables – Total market ATC3 CRP Brand Pack Mol(s) NIs count LCMs count NIs YTD sales LCMs YTD sales NI YTD sales LCM YTD sales Source: CTM / IMS data Dec.06
  • 7. CTM deliverables – specific ATC3 Select Class All results filtered on the selected class. New competitors information available. PM can follow up brands/ generics introductions in his market(s). Source: CTM / IMS data Dec.06
  • 8. CTM deliverables – specific CRP Select CRP All results filtered on the selected CRP. Analysis of CRPs YTD growth derived from NIs/LCM. Identify introduced brands by the selected CRP. Source: CTM / IMS data Dec.06
  • 9. CTM analysis – Leading CRPs in LCM Arrange CRPs in terms of YTD LCM value sales. Assess YTD impact of CRP new packs introduced. Source: CTM / IMS data Dec.06
  • 10. CTM analysis – Leading CRPs in NIs Arrange CRPs in terms of YTD Nis value sales. Assess YTD impact of CRP new brands introduced. Source: CTM / IMS data Dec.06
  • 11. CTM analysis – Leading ATC3 in NIs Arranged classes in terms of NIs to identify the attractive markets. Assess current classes that our brands compete in. Source: CTM / IMS data Dec.06
  • 12. CTM analysis – Leading ATC3 in LCMs Arranged classes in terms of LCMs to identify the attractive markets. Assess current classes that our brands compete in. Source: CTM / IMS data Dec.06
  • 13. Sample outputs ading CRPs - LCM Others (180), 23,799,000 , 22% NOVARTIS, 39,246,800 SANOFI AVENTIS, , 35% 2,127,700 , 2% MERCK AG*, 3,043,000 , 3% GLAXOSMITHKLINE*, 3,471,600 , 3% AMOUN PHARM.CO., 3,896,400 , 4% EVA, 4,979,400 , 5% ABBOTT*, 5,117,000 , LCM breakdown per CRP PFIZER*, 8,972,900 , 8% 45,000,000 5% ALTANA*, 7,037,600 , MIACALCIC PLUS LUNDBEC., 6,423,900 , SIRDALUD 2mg 20 7% (08.2006), 615,300 6% 40,000,000 (07.2006), 542,500 VOLTAREN AMP 75mg 6 35,000,000 (04.2006), 6,362,100 CATAFLAM AMP 75mg 6 30,000,000 (04.2006) , 4,156,400 ANAFRONIL 75mg 20 25,000,000 (02.2006), 4,306,600 20,000,000 38.6 Mio CATAFLAM 50mg 20 15,000,000 (02.2006), 13,232,700 10,000,000 FLOTAC (01.2006), 5,000,000 10,031,300 Source: CTM / IMS data Dec.06 - Novartis PH
  • 14. Key success factors Tool update can be done easily without too much technical knowledge (preliminary Dataview and Excel experience). Tool is applied in Novartis Egypt for almost a year and introduced to Novartis KSA from Oct.06. PMs follow up introductions in their markets on monthly basis or during MPH planning. CPO management assess their position in the market and follow up competitor launches on monthly basis or during planning or StratPlan preperation. BD&L can analyze the market and identify attractive markets in terms of number/ value of NIs & LCMs.
  • 15. Conclusion CTM is an easy tool that give more insight about market dynamics. The tool can be adapted easily in different markets from small CPOs to regional level. Many new untapped information can be explored that will support marketing and senior management to analyze market dynamics. Consolidated reports can easily extracted with pivot reports.
  • 16. Thanks 16 Comers To the Market (CTM)-Presentation / Egypt

Hinweis der Redaktion

  1. FF input is validated by IMS MAT units sales per territory and zone. IMS units is fine tuned by two factors: TAR DRs visited against the total market universe. # of boxes sold without RXs.